Akari Therapeutics Plc Stock Performance
| AKTX Stock | USD 1.21 0.09 8.04% |
The firm shows a Beta (market volatility) of -0.34, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Akari Therapeutics are expected to decrease at a much lower rate. During the bear market, Akari Therapeutics is likely to outperform the market. At this point, Akari Therapeutics PLC has a negative expected return of -1.47%. Please make sure to confirm Akari Therapeutics' total risk alpha, as well as the relationship between the kurtosis and price action indicator , to decide if Akari Therapeutics PLC performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Akari Therapeutics PLC has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Last Split Factor 1:20 | Last Split Date 2023-08-17 |
1 | Discretionary transaction by Prudo-chlebosz Raymond of 9210500 shares of Akari Therapeutics at 0.03 subject to Rule 16b-3 | 09/10/2024 |
2 | Rob Bazemore Appointed to the Board of Directors of Akari Therapeutics | 09/17/2024 |
3 | Acquisition by Patel Samir Rashmikant of 175080000 shares of Akari Therapeutics at 0.0015 subject to Rule 16b-3 | 09/30/2024 |
4 | Disposition of tradable shares by Williams Donald A of Akari Therapeutics subject to Rule 16b-3 | 10/01/2024 |
5 | Disposition of 1300000 shares by Grissinger Michael of Akari Therapeutics at 0.0218 subject to Rule 16b-3 | 10/08/2024 |
6 | Acquisition by Patel Samir Rashmikant of 79684000 shares of Akari Therapeutics at 0.0013 subject to Rule 16b-3 | 10/31/2024 |
7 | Akari Therapeutics Announces Successful Completion of Merger of Akari Therapeutics and Peak Bio | 11/14/2024 |
8 | Insider Trading | 11/22/2024 |
| Begin Period Cash Flow | 13.2 M |
Akari |
Akari Therapeutics Relative Risk vs. Return Landscape
If you would invest 368.00 in Akari Therapeutics PLC on September 1, 2024 and sell it today you would lose (247.00) from holding Akari Therapeutics PLC or give up 67.12% of portfolio value over 90 days. Akari Therapeutics PLC is currently does not generate positive expected returns and assumes 7.1161% risk (volatility on return distribution) over the 90 days horizon. In different words, 63% of stocks are less volatile than Akari, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Akari Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Akari Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Akari Therapeutics PLC, and traders can use it to determine the average amount a Akari Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.2072
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | AKTX |
Estimated Market Risk
| 7.12 actual daily | 63 63% of assets are less volatile |
Expected Return
| -1.47 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.21 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Akari Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Akari Therapeutics by adding Akari Therapeutics to a well-diversified portfolio.
Akari Therapeutics Fundamentals Growth
Akari Stock prices reflect investors' perceptions of the future prospects and financial health of Akari Therapeutics, and Akari Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Akari Stock performance.
| Return On Equity | -12.81 | ||||
| Return On Asset | -1.73 | ||||
| Current Valuation | 26.48 M | ||||
| Shares Outstanding | 20.65 M | ||||
| Price To Earning | (2.15) X | ||||
| Price To Book | 3.07 X | ||||
| EBITDA | (16.8 M) | ||||
| Net Income | (10.01 M) | ||||
| Cash And Equivalents | 8.15 M | ||||
| Cash Per Share | 0.14 X | ||||
| Total Debt | 4.58 M | ||||
| Debt To Equity | 0.07 % | ||||
| Current Ratio | 3.73 X | ||||
| Book Value Per Share | (0.04) X | ||||
| Cash Flow From Operations | (16.43 M) | ||||
| Earnings Per Share | (2.58) X | ||||
| Market Capitalization | 30.35 M | ||||
| Total Asset | 4.36 M | ||||
| Retained Earnings | (227.46 M) | ||||
| Working Capital | 1.77 M | ||||
| Current Asset | 69.66 M | ||||
| Current Liabilities | 21.12 M | ||||
About Akari Therapeutics Performance
Evaluating Akari Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Akari Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Akari Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | -281.4 K | -267.3 K | |
| Return On Tangible Assets | (2.31) | (2.42) | |
| Return On Capital Employed | 73.39 | 77.06 | |
| Return On Assets | (2.30) | (2.41) | |
| Return On Equity | 43.70 | 45.89 |
Things to note about Akari Therapeutics PLC performance evaluation
Checking the ongoing alerts about Akari Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Akari Therapeutics PLC help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Akari Therapeutics generated a negative expected return over the last 90 days | |
| Akari Therapeutics has high historical volatility and very poor performance | |
| Akari Therapeutics may become a speculative penny stock | |
| Akari Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (10.01 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Akari Therapeutics PLC currently holds about 8.15 M in cash with (16.43 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.14. | |
| Akari Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from globenewswire.com: Akari Therapeutics Announces Successful Completion of Merger of Akari Therapeutics and Peak Bio |
- Analyzing Akari Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Akari Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Akari Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Akari Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Akari Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Akari Therapeutics' stock. These opinions can provide insight into Akari Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Akari Stock Analysis
When running Akari Therapeutics' price analysis, check to measure Akari Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Akari Therapeutics is operating at the current time. Most of Akari Therapeutics' value examination focuses on studying past and present price action to predict the probability of Akari Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Akari Therapeutics' price. Additionally, you may evaluate how the addition of Akari Therapeutics to your portfolios can decrease your overall portfolio volatility.